赵zhao
Lv4
440 积分
2023-11-20 加入
-
Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study
7天前
已完结
-
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
8天前
已完结
-
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
12天前
已完结
-
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
12天前
已完结
-
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
12天前
已完结
-
Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
13天前
已完结
-
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
1个月前
已完结
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
1个月前
已完结
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
1个月前
已完结
-
Epidemiology of Renal Cell Carcinoma: 2022 Update
1个月前
已完结